KR-12 loaded smart polymeric nanoparticle against multi-drug-resistant Klebsiella Pneumoniae
Castellà Barnaus, Carles
Ferrer-Miralles, Neus, tut. (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Universitat Autònoma de Barcelona. Facultat de Biociències

Data:	2025
Resum:	Antimicrobial resistance (AMR) is a growing global health crisis projected to cause up to 10 million deaths annually by 2050. Klebsiella pneumoniae, a multidrug-resistant (MDR) pathogen, is a leading cause of nosocomial infections and demonstrates high resistance to antibiotics including third generation cephalosporins, carbapenems and colistin. Innovative therapeutic strategies are urgently needed to combat such pathogens. Among these, antimicrobial peptides (AMPs), such as LL-37 and its potent derivative KR-12, have emerged as promising alternatives due to their ability to selectively disrupt bacterial membranes. However, direct AMP delivery faces challenges including short-life, degradation, toxicity, and limited bioavailability. To address delivery barriers, recent advances in nanobiotechnology, especially in the development of biocompatible polymeric nanoparticles, have shown potential for the treatment of bacterial pulmonary infections. Inhalable AMP formulations are of particular interest due to their ability to localize treatment directly to the site of infection, bypass systemic side effects, and enhance peptide stability in the hostile pulmonary environment.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Titulació:	Bioquímica [2500252]
Pla d'estudis:	Grau en Bioquímica [814]
Document:	Treball final de grau

1 p, 3.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Treballs de Fi de Grau > Facultat de Biociències. TFG